Loading...
Market
Impact of IL4RxIL31 on J&J's immunology revenue by end of 2026
5
Resolution / Starting Odds
Significant increase in revenue • 25%
Moderate increase in revenue • 25%
No significant impact on revenue • 25%
Decrease in revenue • 25%
Johnson & Johnson's annual financial reports
Story
Johnson & Johnson Acquires Rights to $1.25 Billion IL4RxIL31 Eczema Treatment
May 28, 2024, 02:55 PM
Johnson & Johnson announced on Tuesday that it has agreed to acquire the rights to an experimental skin disorder treatment from privately held Numab Therapeutics for approximately $1.25 billion. The treatment is a bispecific antibody designed to address atopic dermatitis by targeting two biological pathways associated with inflammation and itching. This acquisition marks Johnson & Johnson's second immunology deal this month, highlighting the company's strategic focus on expanding its immunology portfolio. The bispecific antibody, identified as IL4RxIL31, is in the clinical-stage and is expected to provide a novel approach to treating eczema.
View original story
Similar markets
Significant improvement • 25%
Moderate improvement • 25%
No significant change • 25%
Worsened financial performance • 25%
Significant increase • 25%
Moderate increase • 25%
No significant impact • 25%
Decrease due to other factors • 25%
Exceeds market expectations • 33%
Meets market expectations • 34%
Falls below market expectations • 33%
Significant gain in market share • 33%
Moderate gain in market share • 34%
No significant change in market share • 33%
Less than $500 million • 33%
$500 million - $1 billion • 33%
More than $1 billion • 34%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Less than $1 billion • 33%
Between $1 billion and $2 billion • 33%
More than $2 billion • 33%
Becomes a top 5 vaccine company • 25%
Remains outside top 5 but improves position • 25%
No significant change in market position • 25%
Declines in market position • 25%
Standalone Unit • 25%
Merged with J&J Immunology Division • 25%
Merged with J&J Research and Development • 25%
Dissolved with Assets Redistributed • 25%
Revenue from Imdelltra exceeds $1 billion • 25%
Revenue from Imdelltra is $500 million to $1 billion • 25%
Revenue from Imdelltra is $100 million to $500 million • 25%
Revenue from Imdelltra is less than $100 million • 25%
No further significant lawsuits • 33%
Few minor lawsuits • 33%
Significant new lawsuits • 34%